The importance of these PROTACs as potential radiosensitizers for prostate cancer is emphasized by the study showing that targeted degradation of RT-increased AR with FDA-approved AR degradation enhancer, dimethylcurcumin (ASC-J9), significantly sensitized prostate cancer toward radiation in xenograft models, while conventional anti-androgen drugs, such as enzalutamide, has no radiosensitizing effects (114). The gene discussed is AR; the disease is prostate cancer.